FDA Approves MI Cancer Seek Test as a Groundbreaking Tool for Targeted Cancer Therapy

European Commission Approves BRAFTOVI and MEKTOVI for Lung Cancer

FDA Approves Breakthrough Device: Altius System to Tackle Chronic Amputation Pain

Nipocalimab Submitted to FDA for Treatment of Generalized Myasthenia Gravis

FDA Approves TruSight Cancer Test for Matching Patients with Targeted Therapies

Novel Cancer Drug PT217 Wins FDA Orphan Drug Status for Neuroendocrine Carcinoma

Darolutamide Shows Promise in Phase III ARANOTE Trial for Treating Prostate Cancer

ALTO-100 Trial: Using Cognitive Biomarkers to Personalize Depression Treatment

New Horizons in Schizophrenia Treatment: ALTO-101 Targets Cognitive Dysfunction

FDA Approves Trials for ZW171: A Novel Bispecific Antibody for Hard-to-Treat Cancers

Beyond Visualization: The Promise of VGT-309 in Minimally Invasive Lung Cancer Surgery

New Treatment for AA Hepatitis: Larsucosterol Earns FDA Breakthrough Designation

GenFleet Receives FDA Approval for P3 Trial of GFH925 in Colorectal Cancer Treatment

Roche's Blood Test for Alzheimer's Earns FDA Breakthrough Device Designation

FDA Approves Groundbreaking Gene Therapy for Children with Rare Genetic Disorder

Pancreatic Cancer Therapy Cambritaxestat Receives FDA Orphan Drug Designation

CAR-T Therapy and Multiple Sclerosis: A New Horizon for Disease Management

Digital Therapeutics: The Promise of Virtual Reality Masks in Treating PTSD Symptoms

Natera's Novel Blood Test Signatera Offers New Hope for Early Lung Cancer Detection

Rznomics' RNA-Based Therapy Receives FDA Orphan Drug Status for Liver Cancer

Vergent's VGT-309 Shows Promise in Real-Time Visualization of Tumors During Surgery

FDA Grants Orphan Drug Status to NeoImmuneTech's NT-I7 for Pancreatic Cancer

FDA Grants Breakthrough Device Designation to Amadix's Blood Test PreveCol for CRC

The Global CAR T-Cell Therapy Market's Ascent: From $8.2 B in 2022 to $11.2 B by 2030

New Treatment for Colorectal Cancer: BOLD-100 Shows Positive Results at ASCO GI 2024

Tarsier Pharma Secures FDA Agreement for Phase 3 Trial of Ophthalmic Solution for Uveitis

Castle's Innovative Gene Expression Tests Transform Clinical Decisions for Skin Cancer

Deloitte's Survey Uncovers Optimism and Concerns in Generative AI Adoption

BioTrace: First FDA-Cleared Ultrasound Software for Liver Tumor Response Prediction

Milestone in Women's Health: Qvin's QPad Gains FDA Approval for Menstrual Blood Testing

Bloodstream Infection Treatment: Phase 3 Trial of Mino-Lok Completed

FDA Approves Everest's Nefecon for IgA Nephropathy Treatment

World's First Chronic Migraine Therapy System Successfully Implanted in Six Patients

NeuExcell's AAV Gene Therapy Granted FDA Orphan Drug Designation for Glioma

Medtronic's PulseSelect PFA System Earns FDA Approval for Atrial Fibrillation Treatment

Depixus and Daiichi Sankyo Collaborate to Accelerate RNA-targeted Drug Discovery

NATALEE Trial: Novartis' Kisqali Achieves 25% Reduction in Breast Cancer Recurrence Risk

Servier Unveils Tibsovo Data at ASH Meeting: Acute Myeloid Leukemia Treatment

A New Phase in ALS Treatment: NurOwn Enters a Crucial Stage Following FDA Meeting

AstraZeneca and AbelZeta Jointly Co-Develop CAR-T Cancer Therapy in China

Merck and Acceleration Collaborate to Revolutionize Scientific Discovery with AI

FDA Grants Breakthrough Designation to J&J's TAR-200 for Bladder Cancer

Pfizer Announces Positive Phase 2b Outcomes for Obesity Drug Candidate, Danuglipron

Biohaven Presents Promising Data for new epilepsy drug BHV-7000 at AES 2023

Astellas' Fezolinetant Offers New Hope for Menopause VMS Without Hormones

Everest's Etrasimod Shows Promising Results in P3 Trial for Ulcerative Colitis

BD Launches Vascular Access Ultrasound System to Enhance Clinician Efficiency

New Acoustic AI Model Achieves 83% Accuracy in Detecting Depression

FDA Clears BrainSpec's AI-Powered MRS Platform for Brain Disease Diagnosis

China’s First KRAS Inhibitor GFH925 Receives Priority Review for Lung Cancer